[go: up one dir, main page]
More Web Proxy on the site http://driver.im/ Skip to main content

Advertisement

Springer Nature Link
Log in

Quantitative analysis of conjunctival goblet cells after chronic application of topical drops

  • Original Research
  • Published:
Advances in Therapy Aims and scope Submit manuscript

Abstract

Introduction

Chronic topical glaucoma therapy has been reported to cause deleterious changes to the ocular surface epithelial layers. We compare changes in the number of goblet cells after chronic exposure to latanoprost preserved with 0.02% benzalkonium chloride (BAK) eye drops (Xalatan®; Pfizer, NY, USA), travoprost preserved with sofZia® eye drops (Travatan Z®; Alcon, Fort Worth, TX, USA), or preservative-free artificial tears (Refresh Plus®; Allergan, Irvine, CA, USA).

Methods

Fifteen New Zealand white rabbits were randomised into groups of five (one eye was randomised for treatment) and received once-daily topical application of one of the three treatments for 30 days. Enucleation was performed at the end of the study followed by histologic analysis using mucin stains to identify goblet cells. Goblet cells were quantified and analysed using Student t tests to compare means between groups.

Results

Goblet cells per high-power field were 2.21 (±0.40) in the latanoprost with BAK group, 6.02 (±1.20) in the travoprost with sofZia group, and 7.03 (±1.33) in the preservative-free artificial tear group. The number of goblet cells in the latanoprost with BAK group was significantly lower than the other two groups (P=0.0001). There was no statistically significant difference in goblet cell numbers between the travoprost with sofZia and preservative-free artificial tear group (P=0.24).

Conclusion

Our study illustrates that, in this animal model, once-daily dosing of latanoprost with 0.02% BAK resulted in goblet cell loss compared with dosing with either travoprost with sofZia or preservative-free artificial tears.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
£29.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price includes VAT (United Kingdom)

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Quigley HA, Broman AT. The number of people with glaucoma worldwide in 2010 and 2020. Br J Ophthalmol. 2006;90:262–267.

    Article  PubMed  CAS  Google Scholar 

  2. McKinnon SJ, Goldberg LD, Peeples P, Walt JG, Bramley TJ. Current management of glaucoma and the need for complete therapy. Am J Manag Care. 2008;14(suppl 1):S20–S27.

    PubMed  Google Scholar 

  3. Asbell PA, Potapova N. Effects of topical antiglaucoma medications on the ocular surface. Ocul Surf. 2005;3:27–40.

    PubMed  Google Scholar 

  4. Foulks GN. Topical cyclosporine for treatment of ocular surface disease. Int Ophthalmol Clin. 2006;46:105–122.

    Article  PubMed  Google Scholar 

  5. Noecker RJ, Herrygers LA, Anwaruddin R. Corneal and conjunctival changes caused by commonly used glaucoma medications. Cornea. 2004;23:490–496.

    Article  PubMed  Google Scholar 

  6. Blondin C, Hamard P, Cholley B, Haeffner-Cavaillon N, Baudouin C. In vitro effects of preserved or preservative-free antiglaucoma medications on human complement system. Curr Eye Res. 2003;27:253–259.

    Article  PubMed  Google Scholar 

  7. Malvitte L, Montange T, Vejux A, et al. Measurement of inflammatory cytokines by multicytokine assay in tears of patients with glaucoma topically treated with chronic drugs. Br J Ophthalmol. 2007;91:29–32.

    Article  PubMed  CAS  Google Scholar 

  8. Pisella PJ, Debbasch C, Hamard P, et al. Conjunctival proinflammatory and proapoptotic effects of latanoprost and preserved and unpreserved timolol: an ex vivo and in vitro study. Invest Ophthalmol Vis Sci. 2004;45:1360–1368.

    Article  PubMed  Google Scholar 

  9. De Saint Jean M, Debbasch C, Brignole F, et al. Relationship between in vitro toxicity of benzalkonium chloride (BAC) and preservative-induced dry eye. Adv Exp Med Biol. 2002;506:697–702.

    Google Scholar 

  10. Noecker R. Effects of common ophthalmic preservatives on ocular health. Adv Ther. 2001;18:205–215.

    Article  PubMed  CAS  Google Scholar 

  11. Whitson JT, Cavanagh HD, Lakshman N, Petroll WM. Assessment of corneal epithelial integrity after acute exposure to ocular hypotensive agents preserved with and without benzalkonium chloride. Adv Ther. 2006;23:663–671.

    Article  PubMed  CAS  Google Scholar 

  12. Yee RW, Norcom EG, Zhao XC. Comparison of the relative toxicity of travoprost 0.004% without benzalkonium chloride and latanoprost 0.005% in an immortalized human cornea epithelial cell culture system. Adv Ther. 2006;23:511–519.

    Article  PubMed  CAS  Google Scholar 

  13. Mundorf T, Williams R, Whitcup S, Felix C, Batoosingh A. A 3-month comparison of efficacy and safety of brimonidine-purite 0.15% and brimonidine 0.2% in patients with glaucoma or ocular hypertension. J Ocul Pharmacol Ther. 2003;19:37–44.

    Article  PubMed  CAS  Google Scholar 

  14. Lewis RA, Katz GJ, Weiss MJ, et al. Travoprost 0.004% with and without benzalkonium chloride: a comparison of safety and efficacy. J Glaucoma. 2007;16:98–103.

    Article  PubMed  Google Scholar 

  15. Gipson IK. Distribution of mucins at the ocular surface. Exp Eye Res. 2004;78:379–388.

    Article  PubMed  CAS  Google Scholar 

  16. Pflugfelder SC, De Paiva CS, Villarreal AL, Stern ME. Effects of sequential artificial tear and cyclosporine emulsion therapy on conjunctival goblet cell density and transforming growth factor-beta2 production. Cornea. 2008;27:64–69.

    PubMed  Google Scholar 

  17. De Saint Jean M, Debbasch C, Brignole F, Rat P, Warnet JM, Baudouin C. Toxicity of preserved and unpreserved antiglaucoma topical drugs in an in vitro model of conjunctival cells. Curr Eye Res. 2000;20:85–94.

    Article  Google Scholar 

  18. Harrison JJ, Turner RJ, Joo DA, et al. Copper and quaternary ammonium cations exert synergistic bactericidal and anti-biofilm activity against Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2008. [Epub ahead of print.]

  19. Ingram PR, Pitt AR, Wilson CG, Olejnik O, Spickett CM. A comparison of the effects of ocular preservatives on mammalian and microbial ATP and glutathione levels. Free Radic Res. 2004;38:739–750.

    Article  PubMed  CAS  Google Scholar 

  20. Patarca R, Rosenzwei JA, Zuniga AA, Fletcher MA. Benzalkonium salts: effects on G protein-mediated processes and surface membranes. Crit Rev Oncog. 2000;11:255–305.

    PubMed  CAS  Google Scholar 

  21. Baudouin C. Side effects of antiglaucomatous drugs on the ocular surface. Curr Opin Ophthalmol. 1996;7:80–86.

    Article  PubMed  CAS  Google Scholar 

  22. Kahook MY, Noecker RJ. Comparison of corneal and conjunctival changes after dosing of travoprost preserved with sofZia, latanoprost with 0.02% benzalkonium chloride, and preservative-free artificial tears. Cornea. 2008;27:339–343.

    Article  PubMed  Google Scholar 

  23. Perez-Vilar J, Mabolo R. Gel-forming mucins. Notions from in vitro studies. Histol Histopathol. 2007;22:455–464.

    PubMed  CAS  Google Scholar 

  24. Baudouin C, Riancho L, Warnet JM, Brignole F. In vitro studies of antiglaucomatous prostaglandin analogues: travoprost with and without benzalkonium chloride and preserved latanoprost. Invest Ophthalmol Vis Sci. 2007;9:4123–4128.

    Google Scholar 

  25. Sherwood MB, Grierson I, Millar L, Hitchings RA. Long-term morphologic effects of antiglaucoma drugs on the conjunctiva and Tenon’s capsule in glaucomatous patients. Ophthalmology. 1989;96:327–335.

    PubMed  CAS  Google Scholar 

  26. Broadway DC, Grierson I, O’Brien C, Hitchings RA. Adverse effects of topical antiglaucoma medication. I. The conjunctival cell profile. Arch Ophthalmol. 1994;112:1437–1445.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. University of Colorado Health Sciences Center, Aurora, Colorado, USA

    Malik Y. Kahook

  2. University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA

    Robert Noecker

Authors
  1. Malik Y. Kahook
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Robert Noecker
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Robert Noecker.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kahook, M.Y., Noecker, R. Quantitative analysis of conjunctival goblet cells after chronic application of topical drops. Adv Therapy 25, 743–751 (2008). https://doi.org/10.1007/s12325-008-0078-y

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12325-008-0078-y

Keywords

Search

Navigation